Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

8.29
-0.5150-5.85%
Post-market: 8.290.00000.00%17:36 EDT
Volume:9.00M
Turnover:73.92M
Market Cap:2.12B
PE:-5.51
High:8.46
Open:8.34
Low:8.05
Close:8.81
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:2.10
T/O Rate:4.05%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-4.66
PE(LYR):6.85

Loading ...

BioCryst Pharmaceuticals Faces Competitive Pressure in Hereditary Angioedema Treatment, RBC Says

MT Newswires Live
·
Yesterday

RBC Downgrades BioCryst Pharmaceuticals to Sector Perform From Outperform, Cuts Price Target to $11 From $13

MT Newswires Live
·
Yesterday

BioCryst Pharmaceuticals, Inc. : RBC Cuts to Sector Perform from Outperform; Cuts Target Price to $11 from $13

THOMSON REUTERS
·
Yesterday

U.S. Research Roundup-Caseys General Stores, Targa Resources, United Rentals

Reuters
·
Yesterday

BioCryst Pharmaceuticals Price Target Maintained with a $16.00/Share by Needham

Dow Jones
·
Sep 09

Analysts’ Top Healthcare Picks: Spyre Therapeutics (SYRE), BioCryst (BCRX)

TIPRANKS
·
Sep 09

BioCryst announces Japan MHLW marketing approval for Orladeyo

TIPRANKS
·
Aug 25

BioCryst Says Japan Approves Orladeyo for Pediatric HAE Patients Aged 2-11

Reuters
·
Aug 25

BioCryst Announces Approval of Orladeyo® for Pediatric Hae Patients in Japan

THOMSON REUTERS
·
Aug 25

How Investors May Respond To BioCryst (BCRX) Profit Swing, Raised Revenue Outlook And New ESOP Shares

Simply Wall St.
·
Aug 15

BioCryst Pharmaceuticals (BCRX) Could Be 54% Undervalued Following Strong Earnings Guidance

Simply Wall St.
·
Aug 12

SIGA Technologies Q2 Revenue, Profit Drop as Contract Ends

Reuters
·
Aug 07

BioCryst Pharmaceuticals Price Target Cut to $20.00/Share from $21.00 by Wedbush

Dow Jones
·
Aug 07

Cancer Drugmaker Genmab's H1 Revenue Rises, Lifts FY Outlook

Reuters
·
Aug 06

Zevra Therapeutics Q2 Revenue Rises 53% on Miplyffa Sales

Reuters
·
Aug 06

Sarepta Q2 Results Beat Expectations Despite Lower Sales Stemming from Elevidys Relabel, Unmet Roche Milestone

Reuters
·
Aug 06

Emergent BioSolutions Swings to Q2 Loss on Impairment Charge; to Cut Jobs

Reuters
·
Aug 06

Wedbush Adjusts BioCryst Pharmaceuticals Price Target to $20 From $21, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

BioCryst Pharmaceuticals Q2 Earnings, Revenue Increase; 2026 Revenue Outlook Raised

MT Newswires Live
·
Aug 05

BioCryst Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05